Skip to Main content Skip to Navigation
Journal articles

[Level of evidence for therapeutic drug monitoring of everolimus].

Abstract : Everolimus has proven efficacy for prevention of rejection in adult de novo renal and cardiac transplant recipient in combination with ciclosporine and corticosteroids. Therapeutic drug monitoring (TDM) with target trough concentration (C0) value from 3 to 8 µg/L has been proposed. Through a systematic review of the literature, this work explored a level of recommendation for this TDM. Everolimus exhibits both wide interindividual pharmacokinetic variability and poor relationship between dose and exposure. A good relationship has been reported between C0 values and global exposure to the drug (i.e. AUC). Although C0 > 3 µg/L has been associated with a decreased incidence of rejection, the upper limit of 8 µg/L has never been formally validated. No clinical trial testing other exposure indices or comparing efficacy and/or toxicity of everolimus therapy with and without TDM has been published so far. Consequently the level of recommendation for everolimus monitoring is "recommended".
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00926387
Contributor : Pierre Marquet <>
Submitted on : Thursday, January 9, 2014 - 3:08:58 PM
Last modification on : Tuesday, October 27, 2020 - 2:34:40 PM

Links full text

Identifiers

Collections

Citation

Françoise Goirand, Bernard Royer, Anne Hulin, Franck Saint-Marcoux. [Level of evidence for therapeutic drug monitoring of everolimus].. Thérapie, EDP Sciences, 2011, 66 (1), pp.57-61. ⟨10.2515/therapie/2010025⟩. ⟨inserm-00926387⟩

Share

Metrics

Record views

140